The efficacy of antitumor therapy mainly depends on four critical components: the elicited CD8+ Teffs, the quality of the CD4+ helper T cells, the elimination and/or non-activation of Tregs, and the breakdown of the immunosuppressive tumor microenvironment (3). The gene discussed is CD8A; the disease is neoplasm.